GlassScriptPhysician profile
Neil E Rosenkranz
NPI 1295778173
$4,098.19
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,546 · 2021: $1,061 · 2022: $18.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $876.47 | 2019-2021 | |
| Janssen Biotech, INC. | $643.89 | 2019-2022 | |
| Abbvie INC. | $537.91 | 2019-2021 | |
| Qol Medical, LLC | $464.85 | 2019-2021 | |
| Gilead Sciences, INC. | $250.22 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $200.43 | 2019-2021 | |
| Daiichi Sankyo INC. | $158.62 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $127.05 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.62 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $107.43 | 2020-2021 | |
| Redhill Biopharma INC. | $81.63 | 2020-2021 | |
| Allergan, INC. | $68.55 | 2019-2020 | |
| Celgene Corporation | $67.86 | 2021 | |
| Romark Laboratories, Lc | $67.40 | 2020 | |
| Amgen INC. | $63.38 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.69 | 2020-2021 | |
| Alfasigma USA, INC. | $51.65 | 2020-2021 | |
| Concordia Pharmaceuticals INC. | $42.34 | 2019 | |
| Braintree Laboratories, INC. | $38.96 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.07 | 2021 | |
| Vivus LLC | $19.08 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $16.12 | 2021 | |
| Ucb, INC. | $14.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Rosenkranz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.